Table 4.
Right Hand | Left Hand | Δr-l | ||||||||||||||
2D:4D tertile | G | (95% CI) | P2trend | ρ3 | P4 | G | (95% CI) | P2trend | ρ3 | P4 | G | (95% CI) | P2trend | ρ3 | P4 | |
Testosterone (nmol/L) | I | 0.7 | (0.6 - 0.8) | 0.76 | -0.01 | 0.74 | 0.7 | (0.6 - 0.8) | 0.10 | -0.03 | 0.41 | 0.6 | (0.5 - 0.7) | 0.04 | 0.02 | 0.55 |
II | 0.7 | (0.6 - 0.7) | 0.7 | (0.6 - 0.7) | 0.7 | (0.6 - 0.8) | ||||||||||
III | 0.7 | (0.6 - 0.7) | 0.6 | (0.5 - 0.7) | 0.7 | (0.6 - 0.8) | ||||||||||
Free Testosterone (pmol/L) | I | 6.0 | (4.9 - 7.1) | 0.92 | -0.03 | 0.49 | 6.5 | (5.3 - 7.6) | 0.16 | -0.04 | 0.34 | 5.2 | (4.3 - 6.1) | 0.05 | 0.02 | 0.71 |
II | 6.6 | (5.4 - 7.8) | 6.4 | (5.3 - 7.6) | 6.9 | (5.6 - 8.1) | ||||||||||
III | 5.9 | (4.9 - 7.0) | 5.6 | (4.6 - 6.5) | 6.5 | (5.3 - 7.6) | ||||||||||
Oestradiol (pmol/L) | I | 57.0 | (52.1 - 61.9) | 0.50 | 0.02 | 0.63 | 58.0 | (52.9 - 63.0) | 0.77 | 0.02 | 0.64 | 55.1 | (50.3 - 59.9) | 0.62 | -0.00 | 0.91 |
II | 55.6 | (50.8 - 60.3) | 55.3 | (50.5 - 60.1) | 59.7 | (54.5 - 64.8) | ||||||||||
III | 58.7 | (53.7 - 63.7) | 57.2 | (52.2 - 62.2) | 56.4 | (51.5 - 61.3) | ||||||||||
Free oestradiol (pmol/L) | I | 0.8 | (0.7 - 0.9) | 0.85 | -0.00 | 0.89 | 0.8 | (0.7 - 0.9) | 0.64 | 0.00 | 0.95 | 0.8 | (0.7 - 0.8) | 0.73 | -0.01 | 0.73 |
II | 0.8 | (0.7 - 0.8) | 0.8 | (0.7 - 0.8) | 0.8 | (0.7 - 0.9) | ||||||||||
III | 0.8 | (0.7 - 0.9) | 0.8 | (0.7 - 0.9) | 0.8 | (0.7 - 0.8) | ||||||||||
DHEAS (μmol/L) | I | 1.5 | (1.3 - 1.6) | 0.38 | -0.02 | 0.63 | 1.6 | (1.4 - 1.7) | 0.08 | -0.02 | 0.62 | 1.4 | (1.2 - 1.5) | 0.44 | 0.00 | 0.91 |
II | 1.4 | (1.3 - 1.6) | 1.4 | (1.3 - 1.5) | 1.4 | (1.3 - 1.6) | ||||||||||
III | 1.4 | (1.2 - 1.5) | 1.4 | (1.2 - 1.5) | 1.5 | (1.3 - 1.6) | ||||||||||
Androstenedione (nmol/L) | I | 2.4 | (2.2 - 2.6) | 0.26 | -0.04 | 0.40 | 2.4 | (2.2 - 2.7) | 0.16 | -0.05 | 0.27 | 2.2 | (2.0 - 2.4) | 0.10 | 0.01 | 0.77 |
II | 2.3 | (2.1 - 2.5) | 2.3 | (2.1 - 2.5) | 2.3 | (2.1 - 2.5) | ||||||||||
III | 2.2 | (2.1 - 2.4) | 2.3 | (2.1 - 2.4) | 2.4 | (2.2 - 2.6) | ||||||||||
Oestrone sulphate (ng/mL) | I | 1.1 | (1.0 - 1.2) | 0.68 | -0.03 | 0.44 | 1.1 | (1.0 - 1.2) | 0.35 | -0.01 | 0.85 | 1.0 | (0.9 - 1.1) | 0.51 | -0.01 | 0.72 |
II | 1.0 | (0.9 - 1.1) | 1.0 | (0.9 - 1.1) | 1.0 | (0.9 - 1.1) | ||||||||||
III | 1.0 | (1.0 - 1.1) | 1.0 | (0.9 - 1.1) | 1.1 | (1.0 - 1.1) | ||||||||||
SHGB (nmol/L) | I | 48.3 | (45.3 - 51.3) | 0.26 | 0.06 | 0.13 | 49.5 | (46.4 - 52.6) | 0.74 | 0.04 | 0.26 | 50.0 | (46.8 - 53.1) | 0.65 | 0.02 | 0.66 |
II | 50.8 | (47.7 - 54.0) | 50.0 | (46.9 - 53.0) | 48.6 | (45.6 - 51.6) | ||||||||||
III | 50.6 | (47.5 - 53.8) | 50.2 | (47.1 - 53.3) | 50.9 | (47.8 - 54.1) |
1Estimates from linear mixed models of the logarithm of hormone concentration on 2D:4D tertiles with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
2From likelihood ratio test for linear trend across 2D:4D tertiles.
3Standardised regression coefficients (correlations) from linear mixed models of the logarithm of hormone concentration on continuous 2D:4D with laboratory batch entered as a random intercept, adjusted for ethnicity, age at blood draw, BMI, smoking status, previous oral contraceptive and HRT use, parity, duration of lactation, and age at menarche.
4From likelihood ratio test of ρ.